Related Experiment Video
Updated: Apr 29, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Targeting LDL: is lower better and is it safe?
Evan A Stein1, Frederick J Raal2
1Department of Pathology & Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45215, USA.
Insights
Reducing low-density lipoprotein cholesterol (LDL-C) significantly lowers cardiovascular disease (CVD) risk. New research explores the safety and efficacy of achieving very low LDL-C levels, particularly with PCSK9 inhibitors.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacology
Background:
- Low-density lipoprotein cholesterol (LDL-C) is a primary target for cardiovascular disease (CVD) risk reduction.
- Established outcome trials confirm LDL-C reduction benefits, even at levels below 1.8 mmol/L.
Purpose of the Study:
- To evaluate the benefits of achieving even lower LDL-C levels than currently targeted.
- To address the accuracy of LDL-C measurement methods at very low concentrations.
- To examine the potential harms associated with very low LDL-C levels.
Main Methods:
- Review of large randomized outcome trials.
- Analysis of LDL-C measurement methodologies, including the Friedewald calculation.
- Assessment of safety data regarding potential adverse events at low LDL-C levels.
Main Results:
- Cardiovascular disease risk reduction is linked to the absolute reduction in LDL-C.
- The Friedewald calculation can underestimate LDL-C values below 1.8 mmol/L, impacting risk assessment.
- Current evidence does not strongly support a link between very low LDL-C and increased risks of cancer, hemorrhagic stroke, or violent death.
Conclusions:
- Achieving very low LDL-C levels, potentially below 1.3 mmol/L, warrants further investigation for CVD risk reduction.
- Accurate LDL-C measurement is crucial for precise risk assessment and treatment guidance.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are expected to provide key insights into the efficacy and safety of extremely low LDL-C levels.
Abstract:
Low density lipoprotein cholesterol (LDL-C) is one of the most validated targets in clinical medicine. Large randomized, outcome trials have demonstrated a clear relationship between reducing LDL-C and cardiovascular disease (CVD) risk, which has been maintained to LDL-C levels of <1.8 mmol/L. To assess the benefit of even lower LDL-C it is important to recognize that CVD risk reduction is related to absolute reduction in LDL-C, not to percent change. Furthermore measurement of LDL-C is also critical as recent studies show the Friedewald calculation significantly underestimates true LDL-C values <1.8 mmol/L, distorting the relationship with CVD risk reduction. Discussion of potential harm from low, or lower, LDL-C has centered on cancer, hemorrhagic stroke, and violent death, but there is little evidence from outcome trials to show a relationship with low LDL-C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors which will reduce LDL-C well below 1.3 mmol/L, will likely provide the clearest answer to both the question of efficacy and safety of low LDL-C within the next few years.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements

